Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Non-Current Liabilities (2020 - 2022)

Ovid Therapeutics (OVID) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $26.1 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Total Non-Current Liabilities rose 59.67% year-over-year to $26.1 million, compared with a TTM value of $26.1 million through Mar 2022, up 59.67%, and an annual FY2021 reading of $14.8 million, down 54.18% over the prior year.
  • Total Non-Current Liabilities was $26.1 million for Q1 2022 at Ovid Therapeutics, up from $14.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $32.3 million in Q4 2020 and bottomed at $10.1 million in Q3 2021.
  • Average Total Non-Current Liabilities over 3 years is $18.2 million, with a median of $14.9 million recorded in 2020.
  • The sharpest move saw Total Non-Current Liabilities tumbled 64.0% in 2021, then skyrocketed 59.67% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $32.3 million in 2020, then plummeted by 54.18% to $14.8 million in 2021, then soared by 76.37% to $26.1 million in 2022.
  • Business Quant data shows Total Non-Current Liabilities for OVID at $26.1 million in Q1 2022, $14.8 million in Q4 2021, and $10.1 million in Q3 2021.